Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 5,087 recruiting studies in this area right now.
By phase
- Not applicable2,108
- Phase 21,118
- Phase 1824
- Phase 1/Phase 2483
- Phase 3349
- Phase 4127
- Phase 2/Phase 378
Top conditions
- Multiple Myeloma332
- Acute Myeloid Leukemia292
- Lymphoma182
- Sickle Cell Disease140
- Myelodysplastic Syndromes129
- Acute Lymphoblastic Leukemia123
- Chronic Lymphocytic Leukemia100
- Leukemia100
- Follicular Lymphoma74
- Hematologic Malignancy68
- Myelodysplastic Syndrome68
- Hodgkin Lymphoma67
- Mantle Cell Lymphoma62
- Anemia60
- Diffuse Large B Cell Lymphoma57
- Lymphedema49
- Non-Hodgkin Lymphoma49
- Small Lymphocytic Lymphoma49
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China148
- M.D. Anderson Cancer Center147
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University68
- Memorial Sloan Kettering Cancer Center65
- City of Hope Medical Center61
- Mayo Clinic61
- Assistance Publique - Hôpitaux de Paris46
- St. Jude Children's Research Hospital43
- Peking University People's Hospital41
Where studies are running
- California405
- Texas186
- Maryland149
- Alabama148
- Arizona124
- Florida111
- Massachusetts101
- New York98
- Ohio70
- Minnesota68
Recruiting studies5,087 total
- NCT05214391RecruitingPhase 2
Zanubrutinib for chronic immune low platelets after prior treatments
This Phase 2 study looks at zanubrutinib, a new medication, in people with immune thrombocytopenia (ITP) whose low platelet count has lasted more than 3 months and has not responded to prior steroid and other treatments. It may help raise platelets and reduce bleeding risk when other therapies have not worked.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT05214612Recruiting
Predictors of outcomes in myasthenia gravis
This study looks at what helps predict outcomes in people with myasthenia gravis (MG). It may help doctors better forecast how MG will progress and which factors matter most for recovery and long-term health.
AsyutAges 16 years+ - NCT05219110Recruiting
More fluids for children sick with toxin E. coli
This study looks at whether giving extra (hyper) fluids early helps children with a high-risk E. coli stomach infection. The goal is to improve outcomes by supporting the kidneys during the illness.
Birmingham, AlabamaAges 9 months–21 years - NCT05219721RecruitingPhase 1
CAR T-cell study for relapsed multiple myeloma with GPRC5D
This Phase 1 trial tests a CAR T-cell treatment made to target a protein called GPRC5D on myeloma cells. It may help patients whose multiple myeloma or plasma cell leukemia has come back or stopped responding to prior treatments.
Wuhan, HubeiAges 18–75 - NCT05219903Recruiting
Study of children with eosinophilic gut disorders
This study looks at children ages 0–18 with eosinophilic gut disorders (EGIDs) to better understand these conditions and how they are managed. It may help doctors improve care by comparing real-world information from patients followed at participating hospitals.
PaviaAges birth–18 years - NCT05223413Recruiting
Remote arm treatment to protect the heart during chemo
This trial studies whether a simple “remote conditioning” treatment on the arm can help protect the heart while you receive chemotherapy that includes anthracyclines. If you’re at higher risk for heart damage from chemo, this may reduce risk and help monitor heart function over time.
AarhusAges 18–99 - NCT05231135Recruiting
Registry study for lymphoma in people living with HIV
This study keeps a registry (a protected health record database) of adults with lymphoma who also have HIV. The goal is to better understand lymphoma in people with HIV and how they’re diagnosed and followed over time.
Munich, Select One OptionAges 18 years+ - NCT05229432Recruiting
Oatmeal meal test to study stomach movement in eosinophilic gastritis
This study looks at how your stomach moves (gastric motility) in people with eosinophilic gastritis, using a special oatmeal meal. The goal is to better understand stomach function and how it may relate to symptoms.
Chicago, IllinoisAges 18–59 - NCT05230680RecruitingPhase 1/Phase 2
Azacitidine with CHOP for newly diagnosed TFH nodal T-cell lymphoma
This trial studies azacitidine plus standard CHOP chemotherapy for newly diagnosed nodal T-cell lymphoma that has a specific “TFH” subtype. It aims to improve treatment control for people with this lymphoma type by testing a new combination in an early-phase study.
SeoulAges 20–85 - NCT05231629RecruitingPhase 2
MRD-guided step-by-step treatment for multiple myeloma
This Phase 2 study tests a treatment plan for newly diagnosed multiple myeloma that changes based on MRD results. MRD is a very sensitive lab test that looks for tiny amounts of remaining cancer, which may help tailor therapy to work better and potentially avoid overtreatment.
Birmingham, AlabamaAges 18 years+ - NCT05237258Recruiting
Compare palliative care approaches for people with high-risk AML
This study tests a specialized (targeted) palliative care program versus usual oncology care for people hospitalized with high-risk acute myeloid leukemia (AML). The goal is to see if this palliative approach improves comfort, support, and care planning during intensive treatment.
Birmingham, AlabamaAges 18–120 - NCT05237986Recruiting
Study brain and thinking effects after CAR T therapy in youth
This study looks at how CAR T-cell treatment affects thinking, learning, and day-to-day brain function in children and young adults with certain blood cancers. You (and a caregiver) may complete online testing so researchers can track these changes over time and whether support is needed.
Los Angeles, CaliforniaAges 5 years+ - NCT05241093RecruitingPhase 2
HYML-122 plus cytarabine for FLT3-positive relapsed AML
This trial studies HYML-122 together with cytarabine to treat adults with FLT3-positive acute myeloid leukemia (AML) that has come back or did not respond to prior treatment. It may help shrink the leukemia and improve blood-count recovery when standard treatments haven’t worked.
Suzhou, JiangsuAges 18 years+ - NCT05241106RecruitingPhase 2
HYML-122 for FLT3-mutated AML that came back or did not respond
This Phase 2 trial studies HYML-122 in adults with acute myeloid leukemia (AML) that has either come back or did not respond to prior treatment. It targets tumors with an FLT3 mutation and may offer a new treatment option if your AML is resistant or relapsed.
Suzhou, JiangsuAges 18 years+ - NCT05242055Recruiting
Tracking and treating chronic kidney disease risk
This trial looks at how well an integrated program for identifying and treating people at risk for chronic kidney disease (CKD) can improve outcomes. It may help by catching problems earlier and guiding treatment sooner.
Beijing, Beijing MunicipalityAges 18–100 - NCT05243797RecruitingPhase 3
Teclistamab plus lenalidomide maintenance after transplant
This trial tests whether adding teclistamab to lenalidomide (or using teclistamab alone) helps keep newly diagnosed multiple myeloma from coming back after an autologous stem cell transplant. It’s comparing these options to lenalidomide alone as long-term maintenance.
Phoenix, ArizonaAges 18 years+ - NCT05243212RecruitingPhase 1/Phase 2
CAR-T cell therapy for multiple myeloma
This Phase 1/2 study tests a personalized CAR-T cell treatment that targets a protein called BCMA on myeloma cells. It’s designed for people with multiple myeloma who have already tried several other treatments and still have measurable disease.
Ramat GanAges 18 years+ - NCT05245487Recruiting
Study of blood samples in older people with relapsed lymphoma
This study looks at blood (“hematopoietic”) information in people age 60+ with relapsed B-cell non-Hodgkin lymphoma who need an additional round of treatment. It may help researchers understand changes in the body during active lymphoma therapy.
CopenhagenAges 60 years+ - NCT05245656RecruitingPhase 2
Rituximab plus chemo plans for older mantle cell lymphoma
This Phase 2 trial studies whether an “extra chemo” schedule (adding cytarabine) can work better than a standard rituximab-bendamustine plan in older people with mantle cell lymphoma. It compares two treatment sequences to see which one helps patients live longer and respond better with acceptable safety.
Seoul, Gangnam-GuAges 60 years+ - NCT05246345Recruiting
Study for chronic lymphocytic leukemia after venetoclax failure
This study looks at why chronic lymphocytic leukemia may stop responding after a medicine called venetoclax. By analyzing tumor samples, researchers hope to better understand resistance and guide future treatment options.
AmiensAges 18 years+ - NCT05251493RecruitingPhase 3
Iron infusions in pregnancy: compare two iron medicines
This trial tests which iron infusion works best to treat iron deficiency anemia during pregnancy—ferric derisomaltose versus iron sucrose. It may help you raise your iron levels and improve anemia symptoms while being closely monitored with blood tests and follow-up visits.
Regina, SaskatchewanAges 18–50 - NCT05253495RecruitingPhase 2
Targeted immunotherapy added to chemotherapy and radiation for lymphoma
This Phase 2 trial tests whether adding targeted immunotherapy to standard chemotherapy and radiation can improve outcomes in children with certain types of lymphoma. It may help the immune system work better against cancer.
Birmingham, AlabamaAges 3–39 - NCT05255003RecruitingPhase 4
Anticoagulation options for low platelets with cancer blood clots
This trial studies how best to prevent and treat dangerous blood clots in people with cancer who also have very low platelets. It may help guide safer blood-thinner treatment when bleeding risk is high.
Edmonton, AlbertaAges 18 years+ - NCT05254743RecruitingPhase 3
Pirtobrutinib versus ibrutinib for CLL or SLL
This Phase 3 trial compares two oral medicines—pirtobrutinib and ibrutinib—in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who need treatment. It’s designed to see which drug works better and is easier to take, especially for people with a specific genetic change in the cancer (17p deletion).
Anaheim, CaliforniaAges 18 years+
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 5,087 recruiting hematology studies from the U.S. registry right now, out of 7,715 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.